查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678785

全球遠視治療市場 - 2025 至 2033 年

Global Hyperopia Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球遠視治療市場規模達到 34.2736 億美元，預計到 2033 年將達到 66.5186 億美元，2025-2033 年預測期內的複合年成長率為 7.5%。

執行摘要

遠視是兒童和成人常見的屈光疾病，需要定期評估和治療以防止將來出現併發症。成人遠視與某些問題有關，需要定期評估。此項活動回顧了遠視的評估和管理，以便進行長期預防。

市場動態：

促進因素與約束因素

遠視盛行率不斷上升

推動遠視治療市場的主要因素之一是遠視盛行率的不斷上升，尤其是在老年族群。老花眼和遠視是由於眼球晶狀體的自然退化而導致的疾病，隨著年齡的成長，這種疾病會削弱人們聚焦鄰近物體的能力。

例如，病理性遠視的盛行率遠低於生理性（簡單性和功能性）遠視。眼軸長度的減少最常導致遠視。美國遠視的總盛行率約 10%，約有 1,400 萬人患有遠視。輕度遠視是影響大多數足月新生兒的疾病。約有 4-9% 的嬰兒在 6-9 個月大時患有遠視，而到 12 個月大時患病率約為 3.6%。

因此，遠視盛行率不斷上升，尤其是在老年人中，這推動了對眼鏡、隱形眼鏡和屈光手術等矯正解決方案的需求，約有 10% 的美國人口受到影響，對有效治療方案的需求持續成長。

治療後併發症和副作用的風險

遠視治療市場面臨挑戰，因為 LASIK、PRK 和晶狀體植入等手術干預存在治療後併發症和副作用的風險。這些風險可能導致眼乾澀、眩光、光暈和視力退化等不良影響，增加費用和恢復時間。這使得患者不願意考慮先進的遠視治療，限制了其採用並影響了市場成長。

例如，根據 NCBI 最近的研究表明，矯正鏡片可以有效控制遠視，但由於潛在的副作用，手術治療需要仔細選擇患者並進行諮詢。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 遠視盛行率不斷上升
      • 基於眼部生物力學的客製化雷射手術興起
    • 限制
      • 治療後併發症和副作用的風險
      • 治療費用高昂
    • 機會
      • 拓展新興市場
    • 影響分析

第5章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 管道分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：按類型

  • 軸性遠視
  • 曲率遠視
  • 指數遠視
  • 位置性遠視

第 7 章：按治療類型

  • 眼鏡和隱形眼鏡
  • 屈光手術

第 8 章：依年齡層

  • 兒科
  • 成年人
  • 老年

第 9 章：按最終用戶

  • 醫院
  • 眼科診所和眼科護理中心
  • 門診手術中心 (ASC)
  • 零售及網上眼鏡店

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Zeimer Ophthalmic Systems AG
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Carl Zeiss Meditec AG
  • ALCON Inc
  • Bausch Health Companies Inc.
  • Johnson & Johnson Vision
  • NIDEK CO. LTD
  • Essilor Luxottica (Essilor Ltd)
  • The Cooper Companies Inc
  • Ophtec
  • Staar Surgical
  • Similar data will be provided for each market player.
  • SCHWIND 眼科技術解決方案有限公司
    • 管道產品描述
    • 產品關鍵績效指標 (KPI)
    • 主要活動
    • 市場進入時間表
    • 產品滲透率
    • 銷售估計和預測
  • ORA公司
  • Cloudbreak 治療公司
  • 將為每個市場參與者提供類似的資料。

第 12 章：附錄

簡介目錄
Product Code: PH9278

The global hyperopia treatment market reached US$ 3,427.36 million in 2024 and is expected to reach US$ 6,651.86 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Executive Summary

Hyperopia, a prevalent refractive condition in both children and adults, requires regular assessment and treatment to prevent future complications. Adult hyperopia is linked to certain issues, necessitating regular assessment. This activity reviews hyperopia evaluation and management for long-term prevention.

Market Dynamics: Drivers & Restraints

Growing Prevalence of Hyperopia

One of the primary factors driving the hyperopia treatment market is the increasing prevalence of hyperopia, particularly among the elderly population. Presbyopia and hyperopia are conditions that result from the natural deterioration of the eye's lens, which impairs the ability of individuals to focus on adjacent objects as they age.

For instance, pathologic hyperopia is considerably less prevalent than physiologic (Simple and Functional) hyperopia. A reduction in axial length most frequently causes hyperopia. The United States has an overall prevalence of hyperopia of approximately 10%, translating to approximately 14 million individuals. Mild hyperopia is a condition that affects the majority of full-term neonates. Approximately 4-9% of infants are hyperopic by the age of 6-9 months, and the prevalence is approximately 3.6% by the age of 12 months.

Hence, the increasing prevalence of hyperopia, particularly among the elderly, which drives demand for corrective solutions like eyeglasses, contact lenses, and refractive surgeries with around 10% of the U.S. population affected, the need for effective treatment options continues to grow.

Risk of Post-Treatment Complications and Side Effects

The hyperopia treatment market faces challenges due to the risk of post-treatment complications and side effects from surgical interventions like LASIK, PRK, and lens implantation. These risks can lead to adverse effects like dry eyes, glare, halos and vision regression, increasing the cost and recovery time. This discourages patients from considering advanced hyperopia treatments, limiting their adoption and impacting market growth.

For instance, according to NCBI recent studies indicate that corrective lenses effectively manage hyperopia, but surgical treatments require careful patient selection and counseling due to potential side effects.

Segment Analysis

The global hyperopia treatment market is segmented based on type, treatment type, age group, end user and region.

Treatment Type:

Eye Glasses & Contact Lenses in the treatment type segment is expected to dominate the hyperopia treatment with the highest market share

Hyperopia can be corrected using aspheric high-index lenses or spherical lenses, depending on the strength of the prescription. High-index lenses are thinner and lighter, with a slimmer profile. Anti-reflective coatings are recommended for glasses. Spherical lenses can also correct hyperopia. Wearing options include daily disposable and weekly or monthly contact lenses. Eye Glasses and contact lens prescriptions for farsightedness usually start with plus numbers. Both lenses are suitable for higher prescriptions and offer a slimmer profile.

For instance, Johnson & Johnson Vision Care has approved ACUVUE Theravision with Ketotifen, an etafilcon A drug-eluting contact lens with ketotifen. The FDA-approved lenses contain 19 mcg of ketotifen, an established antihistamine. This marks the first in a new category of contact lenses for those with allergic eye itch, offering a new wearing experience.

Moreover, both contact lenses and eyeglasses contribute to the correction of refractive errors by altering the manner in which light is reflected and bent into the retina. Typically, eyeglasses that correct for farsightedness are larger in the midsection because they are often correcting for a "plus prescription" and a cornea that is too flat. If the prescription is substantial, this may result in a magnified or "bug eye" appearance.

Geographical Analysis

North America is expected to hold a significant position in the hyperopia treatment market with highest market share

North America holds a substantial position in the hyperopia treatment market and is expected to hold most of the market share owing to FDA approvals, advanced healthcare infrastructure, advanced technologies and rising awareness. The aging population, ophthalmic device manufacturers, and favorable reimbursement policies contribute to market growth. The surge in customized procedures and premium intraocular lenses strengthens the market.

For instance, in January 2025, the U.S. FDA approved the excimer laser MEL 90 from Zeiss Meditech for myopia, hyperopia and mixed astigmatism. The laser integrates into Zeiss' Corneal Refractive Workflow, complementing Visumax 800 and SMILE pro software, ensuring efficient surgical correction with positive outcomes.

Hence, the FDA has approved the Zeiss Meditech MEL 90 excimer laser, boosting the hyperopia treatment market by expanding surgical options, improving procedural efficiency, and precision, thus driving innovation and adoption of laser-based hyperopia treatments.

Competitive Landscape

The major global players in the hyperopia treatment market include Zeimer Ophthalmic Systems AG, Carl Zeiss Meditec AG, ALCON Inc, Bausch Health Companies Inc, Johnson & Johnson Vision, NIDEK CO. LTD, Essilor Luxottica (Essilor Ltd), the Cooper Companies Inc, Ophtec, Staar Surgical and among others.

Key Developments

  • In August 2024, ZEISS Medical Technology unveiled its latest cataract and corneal refractive workflow innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference. The company is the first to offer hyperopia treatment with lenticule extraction using SMILE pro in CE markets. ZEISS also celebrates surpassing the 10 million marks for lenticule extraction procedures with ZEISS SMILE and ZEISS SMILE pro. The company will introduce advanced optical and digital ophthalmic microscopes and showcase its enhanced IOL portfolio.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

The global hyperopia treatment market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Hyperopia
      • 4.1.1.2. Rise in Customized Laser Surgery Based on Eye Biomechanics
    • 4.1.2. Restraints
      • 4.1.2.1. Risk of Post-Treatment Complications and Side Effects
      • 4.1.2.2. High Cost of Treatment Procedures
    • 4.1.3. Opportunity
      • 4.1.3.1. Expansion into Emerging Markets
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Supply Chain Analysis
  • 5.9. Patent Analysis
  • 5.10. SWOT Analysis
  • 5.11. Unmet Needs and Gaps
  • 5.12. Recommended Strategies for Market Entry and Expansion
  • 5.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.14. Pricing Analysis and Price Dynamics
  • 5.15. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Axial Hyperopia*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Curvature Hyperopia
  • 6.4. Index Hyperopia
  • 6.5. Positional Hyperopia

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Eye Glasses & Contact Lenses*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Refractive Surgery

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adults
  • 8.4. Geriatric

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ophthalmic Clinics & Eye Care Centers
  • 9.4. Ambulatory Surgical Centers (ASCs)
  • 9.5. Retail & Online Optical Stores

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. Latin America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Mexico
      • 10.4.7.2. Brazil
      • 10.4.7.3. Argentina
      • 10.4.7.4. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Zeimer Ophthalmic Systems AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Carl Zeiss Meditec AG
  • 12.3. ALCON Inc
  • 12.4. Bausch Health Companies Inc.
  • 12.5. Johnson & Johnson Vision
  • 12.6. NIDEK CO. LTD
  • 12.7. Essilor Luxottica (Essilor Ltd)
  • 12.8. The Cooper Companies Inc
  • 12.9. Ophtec
  • 12.10. Staar Surgical
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. SCHWIND eye-tech-solutions GmbH*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. ORA, Inc
  • 12.13. Cloudbreak Therapeutics
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us